Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APP-study: low-dose atropine for prevention of childhood myopia progression
2018-001286-16Phase 2Completed
- Sponsor
- Rigshospitalet
- Start
- May 2018
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in myopia and myopic maculopathy (MM) comparing Atropine low-dose arm with Placebo arm (2 arms). Primary endpoint: Axial length elongation at 36 months. Started May 2018; status: completed.
02
Drugs
atropine
03
Conditions
myopiamyopic maculopathy (MM)
Beyond the preview
Go deeper on 2018-001286-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001286-16.